ClinicalTrials.gg
CompletedNCT01755546Updated Oct 18, 2018Results posted

Long-term Open-Label Safety Study to Evaluate EN3409

A Phase 3 interventional study of EN3409 in Low Back Pain, Osteoarthritis and Neuropathic Pain, sponsored by BioDelivery Sciences International. Completed at 57 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
84th of 623
304 · median 79
Started
2012
with 30 others
Phase 3
62 of 712
1 open now
Registered
226th of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 84th largest by enrollment of the 623 interventional ones that give a count, is one of 31 that started in 2012, is one of 62 in phase 3, and was the 226th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of the long-terms study is to evaluate the safety, tolerability, and analgesic efficacy of EN3409 in subjects with moderate to severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

03

Conditions studied

  • Low Back Pain
  • Osteoarthritis
  • Neuropathic Pain

Keywords

  • Chronic Pain
  • CLBP
  • Chronic Low Back Pain
  • Back Pain
  • Osteoarthritis
  • OA
  • Neuropathic Pain
  • Nerve pain
  • Painful neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects who are practicing abstinence or using a medically acceptable form of or have been , biologically sterile, or surgically sterile for more than 1 year
  • Male subjects who are practicing abstinence, surgically sterile, or are using a medically acceptable form of contraception
  • De Novo subject with a clinical diagnosis of moderate to severe noncancer-related CP (eg, CLBP, OA, neuropathic pain) for ≥ 3 months
  • De Novo subject that is treating their CP with a stable daily maintenance dose of ATC opioid analgesic medication equivalent to ≥ 60 mg and ≤ 160 mg Morphine Sulfate Equivalent (MSE) per day for ≥ 4 weeks
  • Stable health, as determined by the Principal Investigator
  • Subject is willing and able to comply with all protocol required visits and assessments
  • Rollover subject who has completed the 12-week Double-blind Treatment Phase in the EN3409-307/308 clinical study

Exclusion criteria

Exclusion Criteria:

  • A history or current evidence of any disorder or any other condition, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
  • Females who are pregnant, breastfeeding, or plan to become pregnant during the study
  • Current cancer-related pain or received chemotherapy within 6 months of screening
  • Subjects receiving opioid analgesic medication \< 60 mg MSE per day within 28 days of screening
  • De novo subjects receiving opioid analgesic medication at doses of > 160 mg MSE per day within 28 days of screening
  • Subjects with a history of other chronic painful conditions, other than the index CP condition, which require frequent analgesic medication
  • Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis
  • History of allergy or to any opioid or acetaminophen
  • Surgical procedure for relief of pain within 6 months, or nerve/plexus block within 28 days of screening
  • Hypokalemia or clinically unstable cardiac disease
  • Moderate to severe hepatic impairment
  • Moderate to severe renal impairment
  • Current or past history of alcohol or substance
  • Positive urine toxicology screen for drugs of abuse
  • History of abnormalities on physical exam, vital signs, , or lab values
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    EN3409

    Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily

    Drug: EN3409

Interventions

  • DrugEN3409

    Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily

    Also known as: Buprenorphine HCI Buccal Film 300-900 mcg twice daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score

    The NRS Pain intensity score is a segmented version of a visual analog scale used to measure pain. The scale is from 0 (no pain) to 10. Scores between greater than 0 and 3 are considered mild pain, scores from greater than 3 to 6 are moderate and greater than 6 to 10 are severe. The daily average is calculated and the change from baseline at week 48 is presented.

    Time frame: 48 weeks

07

Results

Posted Sep 12, 2018

Participant flow

Screened and Taper (Rollover and DeNovo)
Participant flow — Screened and Taper (Rollover and DeNovo)
MilestoneOverall
Started304
Completed294
Not completed10
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up1
Withdrew: Any other reason and screen failures5
Titration Phase
Participant flow — Titration Phase
MilestoneOverall
Started294
Completed224
Not completed70
Withdrew: Adverse event11
Withdrew: Lack of efficacy18
Withdrew: Protocol violation9
Withdrew: Lost to follow-up2
Withdrew: Other and continuing22
Withdrew: Withdrawal by subject8
Long Term Treatment
Participant flow — Long Term Treatment
MilestoneOverall
Started224
Completed103
Not completed121
Withdrew: Adverse event12
Withdrew: Lack of efficacy6
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject35
Withdrew: Lost to follow-up17
Withdrew: Other and ongoing41

Outcome measures

PrimaryChange From Baseline to Week 48 in Daily Average NRS Pain Intensity Score

The NRS Pain intensity score is a segmented version of a visual analog scale used to measure pain. The scale is from 0 (no pain) to 10. Scores between greater than 0 and 3 are considered mild pain, scores from greater than 3 to 6 are moderate and greater than 6 to 10 are severe. The daily average is calculated and the change from baseline at week 48 is presented.

Time frame:
48 weeks
Reported as:
Mean · units on a scale
Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score
units on a scaleOverall
Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score0.2 ± 1.78

Adverse events

Collected over 48 Weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall—12/224 (5.4%)115/224 (51.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventOverall
BronchitisInfections and infestations1/224
CellulitisInfections and infestations1/224
SepsisInfections and infestations1/224
UrosepsisInfections and infestations1/224
SyncopeNervous system disorders1/224
Status migrainosusNervous system disorders1/224
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/224
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/224
NephrolithiasisRenal and urinary disorders1/224
Renal impairmentRenal and urinary disorders1/224
Most frequent other events
Showing 10 of 11
Most frequent other events
EventOverall
NauseaGastrointestinal disorders18/224
Upper respiratory tract infectionInfections and infestations14/224
Back painMusculoskeletal and connective tissue disorders13/224
HeadacheNervous system disorders12/224
VomitingGastrointestinal disorders11/224
DiarrheaGastrointestinal disorders10/224
BronchitisInfections and infestations9/224
ConstipationGastrointestinal disorders9/224
DepressionPsychiatric disorders8/224
NasopharyngitisInfections and infestations7/224

Baseline characteristics

Baseline at start of Long-Term Treatment Phase

Age, Categorical
Age, Categorical(Participants)Overall
<=18 years0
Between 18 and 65 years193
>=65 years31
Age, Continuous
Age, Continuous(Years)Overall
Mean52 ± 11.80
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female125
Male99
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino39
Not Hispanic or Latino185
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native3
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American57
White158
More than one race0
Unknown or Not Reported0
Weight (kg)
Weight (kg)(kilograms)Overall
Mean92.2 ± 21.57
Height (cm)
Height (cm)(centimeters)Overall
Mean169.5 ± 10.39
BMI (kg/m^2)
BMI (kg/m^2)(kg/m^2)Overall
Mean32.1 ± 7.20

2 further baseline measures are reported on the registry.

08

Study locations

57 sites
  • Parkway Medical Center
    Birmingham, Alabama 35215, United States
  • Horizon Research Group, Inc
    Mobile, Alabama 36608, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Global Research, LLC
    Anaheim, California 92804, United States
  • Synergy Clinical Research Center of Escondido
    Escondido, California 92025, United States
  • RX Clinical Research, Inc.
    Garden Grove, California 92843, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90807, United States
  • Adam D. Karns, MD
    Los Angeles, California 90036, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Century Clinical Research, Inc.
    Daytona Beach, Florida 32117, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Florida Health Center
    Fort Lauderdale, Florida 33312, United States
  • Eastern Research, Inc.
    Hialeah, Florida 33013, United States
  • Southeast Clinical Research, LLC
    Jacksonville, Florida 32216, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Research Centers of America, LLC
    Oakland Park, Florida 33334, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Ribo Research LLC DBA Peninsula Research
    Ormond Beach, Florida 32806, United States
  • Gold Coast Research, LLC
    Plantation, Florida 33317, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • National Pain Research Institute, LLC
    Winter Park, Florida 32789, United States
  • River Birch Research Alliance, LLC
    Blue Ridge, Georgia 30513, United States
  • Drug Studies America
    Marietta, Georgia 30060, United States
  • Taylor Research, LLC
    Marietta, Georgia 30060, United States
  • In-Quest Medical Research, LLC
    Norcross, Georgia 30092, United States
  • Global Scientific Innovations
    Evansville, Indiana 47714, United States
  • Integrated Clinical Trials Services, Inc.
    West Des Moines, Iowa 50265, United States
  • Willis-Knighton Physician Network
    Bossier City, Louisiana 71111, United States
  • Clinical Trials Management, LLC
    Metairie, Louisiana 70006, United States
  • Best Clinical Trials, LLC
    New Orleans, Louisiana 70115, United States
  • River Cities Clinical Research Center
    Shreveport, Louisiana 71105, United States
  • New England Center for Clinical Research, Inc.
    Fall River, Massachusetts 02720, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Cadillac Clinical Research
    Cadillac, Michigan 49601, United States
  • The Center for Clinical Trials
    Biloxi, Mississippi 39531, United States
  • Long Island Gastrointestinal Research Group
    Great Neck, New York 11023, United States
  • Upstate Clinical Research Associates
    Williamsville, New York 14221, United States
  • The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Plains Medical Clinic, LLC
    Fargo, North Dakota 58104, United States
  • Clinical Inquest Center, Ltd
    Beavercreek, Ohio 45432, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Optimed Research, Ltd.
    Tiffin, Ohio 44883, United States
  • Brandywine Clinical Research
    Downingtown, Pennsylvania 19335, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Pain Specialists of Charleston, P.A.
    Charleston, South Carolina 29406, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • FutureSearch Clinical Trials
    Austin, Texas 78731, United States
  • KRK Medical Research
    Dallas, Texas 75230, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Advanced Clinical Research of Houston
    Houston, Texas 77062, United States
  • Innovative Clinical Trials
    San Antonio, Texas 78229, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • Clinical Investigations Specialist, Inc.
    Kenosha, Wisconsin 53142, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Oct 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2012
First posted
Dec 24, 2012
Start
Dec 2012
Primary completionActual
Oct 2014
CompletionActual
Nov 2014
Results first posted
Sep 12, 2018
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01755546
Lead sponsor
BioDelivery Sciences International
Responsible party
Sponsor
First posted
Dec 24, 2012
Start date
Dec 2012
Primary completion
Oct 2014
Completion
Nov 2014
Results posted
Sep 12, 2018
Last update
Oct 18, 2018

Study contacts

Andrew Finn, PharmD
study director · BioDelivary Sciences Internantional, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion